Overview: CD11c Flow Cytometry TestIntroduction: The CD11c Flow Cytometry Test detects CD11c markers to diagnose leukemia or lymphoma, causing fever or weight loss. Aligned with 2023 ASH guidelines, it uses flow cytometry for high specificity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in hematology for patients with suspected hematologic malignancies.
Other Names: CD11c Flow Assay, Integrin Alpha X Test.
FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic accuracy.
Historical Milestone: CD11c testing began in the 1990s with leukemia research. Flow cytometry emerged in the 2000s, improving accuracy for marker detection.
Purpose: Diagnoses leukemia or lymphoma, guides treatment, and monitors CD11c markers in patients with fever or weight loss.
Test Parameters: 1. CD11c
Pretest Condition: No fasting required. Collect whole blood or bone marrow at any time. Report symptoms like fever or weight loss, and list medications.
Specimen: 2-5 mL whole blood (EDTA) or 2-5 mL bone marrow (EDTA). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fever, weight loss, or history of leukemia/lymphoma. Include current medications, especially chemotherapeutics.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for cancer therapy.
Procedural Considerations: Uses flow cytometry to detect CD11c markers. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Poor sample quality or low cell yield can affect results. Non-malignant conditions may express CD11c.
Clinical Significance: Positive CD11c expression suggests leukemia or lymphoma, prompting treatment. Negative results may require additional marker testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation.
Additional Supporting Tests: Bone marrow biopsy, other flow cytometry markers, or PET scan to confirm leukemia/lymphoma.
Test Limitations: Non-specific expression may occur in non-malignant conditions. Results require clinical correlation.
References: ASH Leukemia Guidelines, 2023; Blood, Arber DA, 2022.
